Medication info
Telmisartan/Rosuvastatin Calcium (Unrefined)/Ezetimibe Film-Coated Tablet 40/5/10 mg

Telmisartan/Rosuvastatin Calcium (Unrefined)/Ezetimibe Film-Coated Tablet 40/5/10 mg

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›40mg / 1 tabletRosuvastatin Calcium Micronized›5.2mg / 1 tabletEzetimibe›10mg / 1 tablet
Manufacturer / importer
Jongkundang Co., Ltd.
Appearance
Yellow oval film-coated tablet
Packaging
30 tablets/bottle, 3 tablets/bottle, 30 tablets/Blister pack, 10 tablets/Blister pack
Approval status
Active

MFDS item code 202202206 · Approved 2022.05.24 · Insurance code 643309000

Summary

Main use
Treatment of essential hypertension, improvement of dyslipidemia, and reduction of cardiovascular risk
Who takes it
Adults
Adult dose
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of telmisartan and the rosuvastatin/ezetimibe combination. Take 1 tablet once daily with water, with or without food. If possible, it is recommended that the medicine be taken at the same time each day (e.g., in the morning). ○ Telmisartan 1. Essential hypertension Adults: The recommended dose of telmisartan is 40 mg orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. When telmisartan is administered concomitantly with thiazide diuretics such as hydrochlorothiazide, it provides an additional blood pressure-lowering effect. Following a dose increase, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after starting treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose of telmisartan is 80 mg orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg is not known. When initiating telmisartan treatment to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be required. ∘ Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed telmisartan 40 mg once daily. ○ Rosuvastatin/ezetimibe The rosuvastatin/ezetimibe combination is administered once daily, with or without food. Patients should continue a standard cholesterol-lowering diet before and during treatment with the rosuvastatin/ezetimibe combination. The dose of the rosuvastatin/ezetimibe combination should be adjusted according to the patient's baseline LDL-cholesterol level, recommended treatment goal, and response. Primary hypercholesterolemia The dosage range of the rosuvastatin/ezetimibe combination is 5/10mg∼20/10mg once daily. The recommended initial dose is 5/10mg once daily. The dose may be adjusted in patients who require a greater reduction in LDL-cholesterol. After starting treatment with the rosuvastatin/ezetimibe combination or adjusting the dose, check blood lipid levels at intervals of 4 weeks or longer and adjust the dose accordingly; the dose may be increased to a maximum of 20/10mg once daily. Patients taking telmisartan and the rosuvastatin/ezetimibe combination concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.

Ingredients

Manufacturer
Jongkundang Co., Ltd.

Efficacy & effects

Treatment of essential hypertension, improvement of dyslipidemia, and reduction of cardiovascular risk

  • Essential hypertension
  • coronary artery disease
  • peripheral artery disease
  • stroke
  • transient ischemic attack
  • clinical evidence of terminal organ damage
  • high-risk diabetes
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • non-familial hypercholesterolemia
  • mixed dyslipidemia
  • elevated total cholesterol
View approved original text

This medication is prescribed only for patients who need to use both Telmisartan and Rosuvastatin/Ezetimibe. Telmisartan is used for the treatment of essential hypertension and is particularly helpful in reducing the risk of myocardial infarction, stroke, and death from cardiovascular disease in patients over 55 years of age who cannot use ACE inhibitors or are at high risk for cardiovascular disease. Rosuvastatin/Ezetimibe is mainly used for patients with hypercholesterolemia and dyslipidemia, lowering levels of total cholesterol and LDL cholesterol (bad cholesterol) while increasing HDL cholesterol (good cholesterol) to improve cardiovascular health. Therefore, this medication is used to simultaneously improve blood pressure and blood cholesterol management.

How to take

Adult dose

This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of telmisartan and the rosuvastatin/ezetimibe combination. Take 1 tablet once daily with water, with or without food. If possible, it is recommended that the medicine be taken at the same time each day (e.g., in the morning). ○ Telmisartan 1. Essential hypertension Adults: The recommended dose of telmisartan is 40 mg orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. When telmisartan is administered concomitantly with thiazide diuretics such as hydrochlorothiazide, it provides an additional blood pressure-lowering effect. Following a dose increase, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after starting treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose of telmisartan is 80 mg orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg is not known. When initiating telmisartan treatment to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be required. ∘ Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed telmisartan 40 mg once daily. ○ Rosuvastatin/ezetimibe The rosuvastatin/ezetimibe combination is administered once daily, with or without food. Patients should continue a standard cholesterol-lowering diet before and during treatment with the rosuvastatin/ezetimibe combination. The dose of the rosuvastatin/ezetimibe combination should be adjusted according to the patient's baseline LDL-cholesterol level, recommended treatment goal, and response. Primary hypercholesterolemia The dosage range of the rosuvastatin/ezetimibe combination is 5/10mg∼20/10mg once daily. The recommended initial dose is 5/10mg once daily. The dose may be adjusted in patients who require a greater reduction in LDL-cholesterol. After starting treatment with the rosuvastatin/ezetimibe combination or adjusting the dose, check blood lipid levels at intervals of 4 weeks or longer and adjust the dose accordingly; the dose may be increased to a maximum of 20/10mg once daily. Patients taking telmisartan and the rosuvastatin/ezetimibe combination concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.

Precautions

This medication can cause severe damage to the fetus and newborn, so if pregnancy is confirmed, treatment should be discontinued immediately. Serious muscle problems can occur, and if symptoms of acute muscle pain or muscle weakness appear, consult a physician immediately. Patients with poor liver function or liver disease should not take this medication and should have regular liver function tests. It is safer for patients with severely impaired kidney function or certain kidney diseases not to use this medication. Patients who are allergic or hypersensitive to any of the components of this medication should avoid taking it. Patients who excessively consume alcohol or have a history of liver disease should consult a physician before taking this medication and should have regular liver enzyme tests. As this medication can lower blood pressure, caution is advised if symptoms of hypotension appear, and care should be taken when driving or operating dangerous machinery, as drowsiness or dizziness may occur. Drug interactions may occur if taken with certain other medications, so it is important to inform healthcare providers of all medications being taken. There is a risk of hyperkalemia, so it is essential to periodically check serum potassium levels, and special caution should be exercised when taken with potassium supplements or potassium-sparing diuretics. Possible side effects include muscle pain, muscle weakness, rash, liver function abnormalities, indigestion, headache, dizziness, bradycardia, tachycardia, hypotension, orthostatic hypotension, dyspnea, increased sweating, itching, rash, eczema, muscle pain, back pain, muscle cramps, joint pain, limb pain, tendon pain; consult healthcare providers immediately if unusual symptoms occur. Particularly, elderly patients, those with diabetes, patients with impaired kidney or liver function, and those with a history of muscle disease should undergo careful assessment before taking this medication. As this medication contains lactose, patients with lactose intolerance should consult a doctor before use. While taking this medication, it is important to conduct regular blood tests, liver function tests, and kidney function tests to ensure safety.

Side effects

Gastritis, gastroesophageal reflux disease, hemorrhoids, colon polyps, vomiting, headache, increased ALT, increased AST, chest pain, facial swelling, strange sensations, drug intolerance, irritable bowel syndrome, esophagitis, dizziness, drowsiness, neurodegenerative disorders, orthostatic dizziness, migraine, diabetes, glucose tolerance impairment, depression, bronchitis, rhinitis, cystitis, tinea unguium, soft tissue infection, hepatic steatosis, liver dysfunction, liver toxicity, acute hepatitis, toxic hepatitis, increased gamma-glutamyl transferase, increased blood cholesterol, increased blood alkaline phosphatase, irregular heartbeat, osteoarthritis, osteoporosis, musculoskeletal stiffness, musculoskeletal discomfort, muscle weakness, diaphoresis, dermatitis, skin burning sensation, skin disorders, alopecia, oropharyngeal pain, nasal congestion, respiratory disorders, pelvic pain, breast cysts, eyelid ptosis, diabetic retinopathy, ear discomfort, renal dysfunction, benign esophageal neoplasm, upper respiratory infection, urinary tract infection, sepsis, anemia, thrombocytopenia, eosinophilia, hypersensitivity, anaphylactic reaction, hyperkalemia, hypoglycemia, depression, insomnia, anxiety, syncope, visual disturbances, dizziness, bradycardia, tachycardia, hypotension, orthostatic hypotension, dyspnea, abdominal pain, diarrhea, dyspepsia, abdominal bloating, abdominal discomfort, dry mouth, liver function abnormalities, liver disorders, increased sweating, itching, rash, erythema, vascular edema, drug rash, toxic skin rash, eczema, urticaria, myalgia, low back pain, muscle cramps, arthralgia, limb pain, tendon pain, acute renal failure, chest pain, weakness, influenza-like illness, increased serum creatinine, increased serum uric acid, elevated serum creatine kinase, decreased hemoglobin, facial spasms, paresthesia, paralysis, hyperventilation, pneumonia, flushing, erectile dysfunction, loss of appetite, arrhythmia, asthenia, decreased libido, facial edema, alopecia, conjunctivitis, tinnitus, petechiae, headache, dizziness, cough, constipation, nausea, pancreatitis, pruritus, myopathy, rhabdomyolysis, asthenia, polyneuropathy, amnesia, peripheral neuropathy, diarrhea, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms syndrome, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, sleep disorders, nightmares, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, memory decline, forgetfulness, amnesic syndrome, memory disorders, confusion, severe myasthenia, ocular myasthenia, chest discomfort, generalized pain, muscle cramps, gout

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to prevent exposure to air or moisture. It is important to maintain a storage temperature between 1 to 30 degrees Celsius. This will safely preserve the medication's effectiveness.

Appearance and packaging

Appearance

Yellow oval film-coated tablet

Package unit

30 tablets/bottle, 3 tablets/bottle, 30 tablets/Blister pack, 10 tablets/Blister pack

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.